These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38640958)

  • 1. Assessment for Antibodies to Rifapentine and Isoniazid in Persons Developing Flu-Like Reactions During Treatment of Latent Tuberculosis Infection.
    Moro RN; Mehaffy C; De P; Phillips E; Borisov AS; Sterling TR; Dobos KM
    J Infect Dis; 2024 Nov; 230(5):1271-1278. PubMed ID: 38640958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
    Sterling TR; Moro RN; Borisov AS; Phillips E; Shepherd G; Adkinson NF; Weis S; Ho C; Villarino ME;
    Clin Infect Dis; 2015 Aug; 61(4):527-35. PubMed ID: 25904367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial.
    Huang HL; Lee MR; Lee CH; Cheng MH; Lu PL; Sheu CC; Wang JY; Chong IW; Yang JM
    Clin Microbiol Infect; 2024 Nov; 30(11):1410-1417. PubMed ID: 38996972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
    Sun HY; Huang YW; Huang WC; Chang LY; Chan PC; Chuang YC; Ruan SY; Wang JY; Wang JT
    Tuberculosis (Edinb); 2018 Jul; 111():121-126. PubMed ID: 30029896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
    Walker RE; Bass S; Srinivas P; Miranda C; Johnson L; Pallotta AM
    Ann Pharmacother; 2020 May; 54(5):457-463. PubMed ID: 31729245
    [No Abstract]   [Full Text] [Related]  

  • 6. Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis.
    Tseng SY; Huang YS; Chang TE; Perng CL; Huang YH
    J Chin Med Assoc; 2021 Nov; 84(11):993-1000. PubMed ID: 34747900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.
    Sterling TR; Scott NA; Miro JM; Calvet G; La Rosa A; Infante R; Chen MP; Benator DA; Gordin F; Benson CA; Chaisson RE; Villarino ME;
    AIDS; 2016 Jun; 30(10):1607-15. PubMed ID: 27243774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
    Sandul AL; Nwana N; Holcombe JM; Lobato MN; Marks S; Webb R; Wang SH; Stewart B; Griffin P; Hunt G; Shah N; Marco A; Patil N; Mukasa L; Moro RN; Jereb J; Mase S; Chorba T; Bamrah-Morris S; Ho CS
    Clin Infect Dis; 2017 Oct; 65(7):1085-1093. PubMed ID: 28575208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials.
    Moro RN; Scott NA; Vernon A; Tepper NK; Goldberg SV; Schwartzman K; Leung CC; Schluger NW; Belknap RW; Chaisson RE; Narita M; Machado ES; Lopez M; Sanchez J; Villarino ME; Sterling TR
    Ann Am Thorac Soc; 2018 May; 15(5):570-580. PubMed ID: 29393655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
    Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM
    Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
    Bliven-Sizemore EE; Sterling TR; Shang N; Benator D; Schwartzman K; Reves R; Drobeniuc J; Bock N; Villarino ME;
    Int J Tuberc Lung Dis; 2015 Sep; 19(9):1039-44, i-v. PubMed ID: 26260821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination With Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection Among People With HIV.
    Lin KY; Sun HY; Yang CJ; Lu PL; Lee YT; Lee NY; Liou BH; Tang HJ; Lee MH; Wang NC; Chen TC; Hii IM; Huang SH; Lin CY; Tsai CS; Cheng CY; Hung CC;
    Clin Infect Dis; 2024 May; 78(5):1295-1303. PubMed ID: 38051646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment for Tuberculosis Infection With 3 Months of Isoniazid and Rifapentine in New York City Health Department Clinics.
    Stennis NL; Burzynski JN; Herbert C; Nilsen D; Macaraig M
    Clin Infect Dis; 2016 Jan; 62(1):53-59. PubMed ID: 26338781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
    Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
    J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection.
    Huang HL; Lee MR; Cheng MH; Lu PL; Huang CK; Sheu CC; Lai PC; Chen TC; Wang JY; Chong IW
    Clin Infect Dis; 2021 Sep; 73(5):e1064-e1071. PubMed ID: 33215187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.
    Denholm JT; McBryde ES; Eisen D; Street A; Matchett E; Chen C; Shultz TR; Biggs B; Leder K
    Intern Med J; 2017 Dec; 47(12):1433-1436. PubMed ID: 29224209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection-A single center study.
    Yang H; Yang Y; Hu ZD; Xia L; Liu XH; Yu X; Ma JY; Li T; Lu SH
    PLoS One; 2021; 16(6):e0253159. PubMed ID: 34115804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
    Villarino ME; Scott NA; Weis SE; Weiner M; Conde MB; Jones B; Nachman S; Oliveira R; Moro RN; Shang N; Goldberg SV; Sterling TR; ;
    JAMA Pediatr; 2015 Mar; 169(3):247-55. PubMed ID: 25580725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study.
    Surey J; Stagg HR; Yates TA; Lipman M; White PJ; Charlett A; Muñoz L; Gosce L; Rangaka MX; Francis M; Hack V; Kunst H; Abubakar I
    BMC Infect Dis; 2021 Jan; 21(1):90. PubMed ID: 33478428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis.
    Yu YY; Tsao SM; Yang WT; Huang WC; Lin CH; Chen WW; Yang SF; Chiou HL; Huang YW
    Int J Environ Res Public Health; 2019 Dec; 17(1):. PubMed ID: 31892222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.